Black Box Warning Suicidality in Children and Adolescents. Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Drug Name] or any other antidepressant in a child or adolescent must balance this risk with the clinical need. [...]
Continue reading " Drug Safety Revisions: Antidepressants Label Change "
Manufacturer: Novartis Indications: Zoledronic acid injection is indicated for patients with hypercalcemia of malignancy, for patients with multiple myeloma, and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplas-tic therapy. Prostate cancer should improve after treatment with at least one hormonal therapy.
Continue reading " Drug Safety Revisions: Zoledronic Acid (Zometa®) "
Manufacturer: Jones Pharma, Inc. Indications: Levothyroxine canadian has several uses: As replacement or supplemental therapy in patients with congenital or acquired hypothyroidism of any cause, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Suppression of pituitary thyroid-stimulating hormone (TSH) to treat or prevent various types of euthyroid goiters, subacute or chronic lymphocytic thyroiditis [...]
Continue reading " Drug Safety Revisions: Levothyroxine (Levoxyl®) "
Manufacturer: Biogen and Genentech Indications: Rituximab is indicated for relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma and for diffuse, CD20-positive, large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclo-phosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
Continue reading " Drug Safety Revisions: Rituximab (Rituxan®) "
Efavirenz (Sustiva generic) Manufacturer: Bristol-Myers Squibb Indication: This prescription-only agent is used in combination with other medications to treat human immunodeficiency virus (HIV) infection. Reason for FDA Intervention: The product’s labeling has been revised to include safety and efficacy data representing 168 weeks of treatment from Study 006 and other available information.
